Three-quarters of Hungarian Drug Makers count on Rising Revenue in 2010

Three-quarters of Hungarian drug companies expect their revenue to rise in 2010 on the previous year, according to a survey by consultancy PricewaterhouseCoopers (PwC), conducted in December.

Only one-quarter of companies planned big capital expenditures in 2010. Planned investments average about EUR 30 million and none are worth more than EUR 50 million, which is moderate for the sector, according to PwC.
Three-quarters of companies said they planned to continue cost-cutting measures started in 2009.

News Monitoring